Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?Zacks Investment Research · 3 days ago
Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?Zacks Investment Research · Sep 15, 2026
Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare ConferenceGlobeNewsWire · Sep 3, 2026
Deutsche Bank AG Makes New Investment in Aclaris Therapeutics, Inc. $ACRSDefense World · Aug 25, 2026
Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to TradeZacks Investment Research · Aug 10, 2026
Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)GlobeNewsWire · Aug 6, 2026Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.16 | -$0.15 | Beat |
| May 7, 2026 | -$0.16 | -$0.15 | Beat |
| Feb 26, 2026 | -$0.15 | -$0.16 | Miss |
| Nov 6, 2025 | -$0.13 | -$0.12 | Beat |
| Aug 7, 2025 | -$0.13 | -$0.13 | Beat |
| May 8, 2025 | -$0.17 | -$0.12 | Beat |